MedTrace Logo

A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

NCT00974675 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-05-02

Study results available
· View outcomes & findings →

Summary

The study includes participants with moderate asthma who were randomly assigned to receive the study medication (CAT-354) or placebo.

Conditions

  • Moderate Asthma

Interventions

BIOLOGICAL

CAT-354 1mg/kg

CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

BIOLOGICAL

CAT-354 5 mg/kg

CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

BIOLOGICAL

CAT-354 10mg/kg

CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

OTHER

Placebo

Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • MedImmune LLC · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-29
Primary Completion
2007-08-03
Completion
2007-08-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00974675 on ClinicalTrials.gov